Struble, Kimberly <br/><br/>
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  02 2018 
 - 482-491 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.29601  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aminoisobutyric Acids<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Genotype<br/>Hepatitis C--classification<br/>Hepatitis C, Chronic--drug therapy<br/>Heterocyclic Compounds, 4 or More Rings--administration & dosage<br/>Humans<br/>Lactams, Macrocyclic<br/>Leucine--analogs & derivatives<br/>Macrocyclic Compounds--administration & dosage<br/>Proline--analogs & derivatives<br/>Quinoxalines<br/>Risk Assessment<br/>Sofosbuvir--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Sustained Virologic Response<br/>United States<br/>United States Food and Drug Administration<br/>Viral Nonstructural Proteins--antagonists & inhibitors